Corteva (NYSE:CTVA) is a major agribusiness player. Strong Q3 performance and a licensing agreement with Bayer boost its growth outlook.
The seed segment saw 40% EBITDA growth. Crop protection also improved profitability. The company raised full-year guidance.
The "freedom to operate" deal with Bayer expands commercialization opportunities. Analysts see it as a catalyst for future growth.
However, agricultural markets are cyclical, and margin sustainability is a risk. Competition and regulatory hurdles remain.
At Bond.az, we track Corteva's financials and market position.
